Aviva PLC Has $19,576,000 Stake in Regeneron Pharmaceuticals, Inc. (REGN)

Aviva PLC boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.6% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 53,303 shares of the biopharmaceutical company’s stock after buying an additional 3,303 shares during the period. Aviva PLC’s holdings in Regeneron Pharmaceuticals were worth $19,576,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Capital World Investors increased its stake in shares of Regeneron Pharmaceuticals by 6.6% in the third quarter. Capital World Investors now owns 7,810,538 shares of the biopharmaceutical company’s stock worth $3,139,992,000 after buying an additional 483,912 shares during the last quarter. State Street Corp increased its position in shares of Regeneron Pharmaceuticals by 2.2% in the fourth quarter. State Street Corp now owns 3,240,549 shares of the biopharmaceutical company’s stock worth $1,189,574,000 after buying an additional 68,675 shares during the last quarter. BlackRock Fund Advisors increased its position in shares of Regeneron Pharmaceuticals by 3.1% in the third quarter. BlackRock Fund Advisors now owns 2,290,395 shares of the biopharmaceutical company’s stock worth $920,785,000 after buying an additional 68,436 shares during the last quarter. Jennison Associates LLC increased its position in shares of Regeneron Pharmaceuticals by 4.5% in the third quarter. Jennison Associates LLC now owns 2,122,148 shares of the biopharmaceutical company’s stock worth $853,146,000 after buying an additional 91,223 shares during the last quarter. Finally, BlackRock Institutional Trust Company N.A. increased its position in shares of Regeneron Pharmaceuticals by 0.4% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 2,017,842 shares of the biopharmaceutical company’s stock worth $811,213,000 after buying an additional 7,547 shares during the last quarter. 68.83% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) traded up 0.23% during midday trading on Tuesday, hitting $376.52. 991,873 shares of the stock traded hands. The company’s 50-day moving average is $363.00 and its 200-day moving average is $385.93. Regeneron Pharmaceuticals, Inc. has a one year low of $325.35 and a one year high of $452.96. The company has a market cap of $39.58 billion, a PE ratio of 48.90 and a beta of 1.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, February 9th. The biopharmaceutical company reported $3.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.03 by $0.01. The business had revenue of $1.23 billion for the quarter, compared to the consensus estimate of $1.30 billion. Regeneron Pharmaceuticals had a net margin of 18.10% and a return on equity of 22.51%. Regeneron Pharmaceuticals’s quarterly revenue was up 11.7% on a year-over-year basis. During the same quarter last year, the company posted $2.83 earnings per share. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post $13.25 EPS for the current fiscal year.

This piece was reported by sleekmoney and is owned by of sleekmoney. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The original version of this piece can be viewed at http://sleekmoney.com/aviva-plc-has-19576000-stake-in-regeneron-pharmaceuticals-inc-regn/1660955.html.

Several equities analysts recently issued reports on REGN shares. Canaccord Genuity set a $450.00 target price on shares of Regeneron Pharmaceuticals and gave the company a “hold” rating in a research note on Monday, December 12th. BTIG Research reiterated a “neutral” rating on shares of Regeneron Pharmaceuticals in a research report on Thursday, November 17th. Leerink Swann set a $448.00 target price on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday. Robert W. Baird restated a “neutral” rating and set a $369.00 target price (down from $379.00) on shares of Regeneron Pharmaceuticals in a research report on Sunday, January 8th. Finally, Morgan Stanley set a $370.00 price target on Regeneron Pharmaceuticals and gave the company a “hold” rating in a research note on Monday, January 9th. Twelve investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $447.16.

In other news, Director Charles A. Baker sold 3,000 shares of the firm’s stock in a transaction on Monday, December 12th. The shares were sold at an average price of $392.02, for a total value of $1,176,060.00. Following the sale, the director now owns 12,000 shares in the company, valued at $4,704,240. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Sanofi acquired 87,298 shares of the stock in a transaction dated Wednesday, January 11th. The stock was bought at an average price of $369.71 per share, for a total transaction of $32,274,943.58. The disclosure for this purchase can be found here. Company insiders own 10.40% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

5 Day Chart for NASDAQ:REGN

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/aviva-plc-has-19576000-stake-in-regeneron-pharmaceuticals-inc-regn/1660955.html

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *